Next Article in Journal
A Comparative Proteomic Analysis of Pinellia ternata Leaves Exposed to Heat Stress
Next Article in Special Issue
Protein Glutathionylation in Cardiovascular Diseases
Previous Article in Journal
Structural Insights into a Novel Interkingdom Signaling Circuit by Cartography of the Ligand-Binding Sites of the Homologous Quorum Sensing LuxR-Family
Previous Article in Special Issue
Proteomic Analysis Identifies an NADPH Oxidase 1 (Nox1)-Mediated Role for Actin-Related Protein 2/3 Complex Subunit 2 (ARPC2) in Promoting Smooth Muscle Cell Migration
Int. J. Mol. Sci. 2013, 14(10), 20597-20613; doi:10.3390/ijms141020597

The Epidermal Growth Factor Receptor and Its Ligands in Cardiovascular Disease

Jr. 1,2,*
1 Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA 2 Veterans Affairs Medical Center, Iowa City, IA 52242, USA
* Author to whom correspondence should be addressed.
Received: 24 July 2013 / Revised: 20 September 2013 / Accepted: 8 October 2013 / Published: 15 October 2013
(This article belongs to the Special Issue Oxidative Stress in Cardiovascular Disease)
View Full-Text   |   Download PDF [635 KB, uploaded 19 June 2014]   |   Browse Figures


The epidermal growth factor receptor (EGFR) family and its ligands serve as a switchboard for the regulation of multiple cellular processes. While it is clear that EGFR activity is essential for normal cardiac development, its function in the vasculature and its role in cardiovascular disease are only beginning to be elucidated. In the blood vessel, endothelial cells and smooth muscle cells are both a source and a target of EGF-like ligands. Activation of EGFR has been implicated in blood pressure regulation, endothelial dysfunction, neointimal hyperplasia, atherogenesis, and cardiac remodeling. Furthermore, increased circulating EGF-like ligands may mediate accelerated vascular disease associated with chronic inflammation. Although EGFR inhibitors are currently being used clinically for the treatment of cancer, additional studies are necessary to determine whether abrogation of EGFR signaling is a potential strategy for the treatment of cardiovascular disease.
Keywords: EGFR; EGF-like ligands; vascular disease; atherosclerosis; cardiac remodeling EGFR; EGF-like ligands; vascular disease; atherosclerosis; cardiac remodeling
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Makki, N.; Thiel, K.W.; Miller, F.J., Jr. The Epidermal Growth Factor Receptor and Its Ligands in Cardiovascular Disease. Int. J. Mol. Sci. 2013, 14, 20597-20613.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert